Heart Rhythm Society

PrepMD Partners with MediaSphere and Esteemed Cardiac Experts for Groundbreaking Virtual Device Clinic Leadership Summit

Retrieved on: 
Wednesday, February 21, 2024
Consensus, FHRS, MSN, RN, Participation, HRS, Curriculum, Faculty, Heart Rhythm Society, CCDS, Business, Biotronik, Health, Journal, Atrium Health, Partnership

BRAINTREE, Mass., Feb. 21, 2024 /PRNewswire/ -- PrepMD, as the exclusive sponsor, is thrilled to announce its partnership with MediaSphere and distinguished cardiac professionals, including Beth Davenport and Sallie Gustafson, to present the largest-ever virtual accredited Cardiac Device Clinic Leadership Summit.

Key Points: 
  • BRAINTREE, Mass., Feb. 21, 2024 /PRNewswire/ -- PrepMD, as the exclusive sponsor, is thrilled to announce its partnership with MediaSphere and distinguished cardiac professionals, including Beth Davenport and Sallie Gustafson, to present the largest-ever virtual accredited Cardiac Device Clinic Leadership Summit.
  • The summit aims to gather leading experts in cardiac device clinic management for a deep dive into pivotal topics.
  • The summit is privileged to feature a panel of esteemed faculty members, each recognized for their significant contributions to cardiac care:
    Beth Davenport, MSN, RN, Clinical Translation Specialist at Biotronik (Former Director of Virtual Care and Cardiac Device Clinic, Sanger Heart & Vascular ), Charlotte, NC
    Sallie Gustafson, RN, Manager of Device Clinic at Emory Clinic, Emory Healthcare , Atlanta, GA
    Nancy Lee, RN, FHRS, CCDS, Regional Director of Device Operations, Clinical Arrhythmia Device Nurse, Prairie Cardiovascular Consultants, Ltd. , O'Fallon, IL
    Amy Tucker, MSN, RN, CCDS, Nurse Manager, Cardiac Device Clinic, Sanger Heart & Vascular Institute , Charlotte, NC
    The Device Clinic Summit is an essential event for all involved in cardiac device clinic management, offering a crucial forum for improving practices and patient care.
  • For registration and additional details, please visit the official website of the summit , hosted by The Journal of Innovations in Cardiac Rhythm Management™.

StopAfib.org Applauds New Atrial Fibrillation Guidelines to Improve Patient Care

Retrieved on: 
Wednesday, December 13, 2023
Atrial fibrillation, Organization, Disease, AHA, ACC, Diagnosis, Patient, ACCP, American College, Heart Rhythm Society, HRS, Writing, Atrium (heart), Quality of life, American Heart Association, Ventricular fibrillation

In addition to the many healthcare professionals who played a part in developing these guidelines, afib patients were also involved in the writing and peer review processes.

Key Points: 
  • In addition to the many healthcare professionals who played a part in developing these guidelines, afib patients were also involved in the writing and peer review processes.
  • StopAfib.org is immensely grateful to these organizations for including the patient perspective, thereby working to address the needs and concerns of patients.
  • These guidelines will help improve care for afib patients, and emphasizing shared decision-making will help patients feel seen and heard," said Mellanie True Hills, Founder and CEO of StopAfib.org.
  • "As an afib patient, I know that collaboration with the healthcare team is vital for getting the best possible care.

Kestra Medical Technologies Offers Electrophysiology and Cardiology Clinicians Opportunity to Wear ASSURE WCD System at #HRX2023 Conference

Retrieved on: 
Friday, September 22, 2023
Biotechnology, Medical Devices, Health, Health Technology, Cardiology, SVT, Arrest, Health technology, Multimedia, Heart Rhythm Society, Photograph, WCD, Patient, Electrophysiology, Risk, ACE, Conference, Arrhythmia, Female, Supraventricular tachycardia, Medical device

Clinicians that participate will be measured, fit, and trained in the use of a demonstration ASSURE WCD System and experience everyday usage of the ASSURE system while participating in conference activities.

Key Points: 
  • Clinicians that participate will be measured, fit, and trained in the use of a demonstration ASSURE WCD System and experience everyday usage of the ASSURE system while participating in conference activities.
  • View the full release here: https://www.businesswire.com/news/home/20230922082496/en/
    Kestra Medical Technologies launched the ASSURE Clinician Experience (ACE) at The Heart Rhythm Society #HRX2023 Conference in Seattle.
  • The program lets electrophysiology and cardiology clinicians wear and simulate use of the ASSURE WCD System to experience how the system was designed for comfort and to promote patient confidence and usage compliance.
  • (Photo credit: Kestra Medical Technologies, Inc.)
    “Wearable defibrillators (WCDs) work when patients wear them,” said Laura Gustavson, Vice President of Clinical Marketing.

BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations

Retrieved on: 
Wednesday, August 23, 2023
Heart Rhythm Society, Cleveland Clinic, Clinic, Exhibition, HRS, Nation, U.S. News & World Report, Research, History, Ablation, Physician, Electrophysiology, Nautilus, Inc. v. Biosig Instruments, Inc., Cardiology, Arrhythmia, News, PURE, Software, Pharmaceutical industry

Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.

Key Points: 
  • Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.
  • BioSig has made the move to a subscription model so that electrophysiologists and cardiology departments can access the latest features with the ability to customize the rich suite of PURE EP™ software capabilities to suit their needs.
  • During the conference, research conceptualized and spearheaded by Cleveland Clinic’s world-class physician faculty highlighted the PURE EP™ Platform’s ability to optimize ablation procedures.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases

Retrieved on: 
Tuesday, August 22, 2023
Cleveland Clinic, NFT, HFA, New product development, Arrhythmia, Report, Data analysis, Heart Rhythm Society, ATC, Research, FDA, Health, PURE, Automation, Software, Medical device, Medical imaging, Nautilus, Inc. v. Biosig Instruments, Inc.

The novel software features were successfully leveraged for the first time during patient cases conducted at the Kansas City Heart Rhythm Institute (“KCHRI”).

Key Points: 
  • The novel software features were successfully leveraged for the first time during patient cases conducted at the Kansas City Heart Rhythm Institute (“KCHRI”).
  • “With these new features, we enhance PURE EP™’s existing capabilities, providing electrophysiologists with pure, unadulterated cardiac signals in real time,” said Zachary Koch, Principal Advisor of Product Development at BioSig.
  • “PURE EP™’s capabilities have already been instrumental in improving our workflows,” said Dhanunjaya “DJ” Lakkireddy, M.D., Executive Medical Director at the KCHRI.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

LATE-BREAKING TRIAL PRESENTED AT HRS SHOWS MEASURABLE DIFFERENCE IN OUTCOMES BETWEEN PATIENTS BY SEX

Retrieved on: 
Friday, June 9, 2023
Arrhythmia, Heart Rhythm Society, Male, NICM, University, Subcutaneous Implantable Defibrillator (S-ICD), Life, CRT-D, Woman, Research, Tachycardia, Doctor of Philosophy, Physician, Cardiomyopathy, Death, Cardiac resynchronization therapy, Conference, Female, Birth control, Medical device, Nursing, MD, Patient

LAKE OSWEGO, Ore., June 9, 2023 /PRNewswire/ -- Data presented at Heart Rhythm Society's 2023 Conference show a measurable difference in outcomes between male and female patients when looking at one-year ventricular tachyarrhythmia or death rates in patients with non-ischemic cardiomyopathy (NICM) with an ICD or CRT-D.

Key Points: 
  • Historically, women have been underrepresented in studies of patients with implantable cardiovascular medical devices, making it impossible to draw measurable conclusions of differences between sex.
  • "The BIO-LIBRA model will lead the way women are enrolled in medical device studies in the next decades," says Dr. Valentina Kutyifa.
  • "A large, properly powered study was much needed to better understand sex-specific outcomes in non-ischemic cardiomyopathy patients, and the BIO-LIBRA study sheds new light on the intricate interconnected relationship between sex and race on outcomes."
  • Contemporary Outcomes of Non-Ischemic Cardiomyopathy Patients with an Implanted Defibrillator or Cardiac Resynchronization Therapy (BIO-LIBRA).

EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results Lead to Early Trial Halt for Success

Retrieved on: 
Monday, May 22, 2023
Freedom, HESTA, Heart, Heart Rhythm Society, Minnow, Late, Heart failure, HRS, Quality of life, Hope, ASX, History, Harvard Medical School, Doctor of Philosophy, Patient, Physician, Electrophysiology, United Kingdom, Mortality, Health, FDA, Massachusetts General Hospital, CRT, Wise, EBR, Safety, Pharmaceutical industry, Medical device, Television, Medicine, MD

SUNNYVALE, Calif., May 22, 2023 /PRNewswire/ -- EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System.

Key Points: 
  • The SOLVE-CRT trial results were presented by Dr. Singh at the Heart Rhythm Society (HRS) 2023 annual meeting, the largest gathering of heart rhythm professionals globally.
  • "We are very excited to announce the success of the SOLVE-CRT pivotal trial," said John McCutcheon, CEO and President of EBR Systems.
  • EBR Systems plans to submit the results of the SOLVE-CRT trial to the FDA later this year for approval in 2024.
  • The excellent SOLVE-CRT results confirm the positive results from earlier published studies of the WiSE CRT System including SELECT-LV, the WiSE European Registry, and the SOLVE-CRT Roll-in study.

Implicity Study Presented in Late-Breaking Clinical Trial Session at Heart Rhythm 2023

Retrieved on: 
Monday, May 22, 2023
HRS, Data management, Mortality, Ren Ci Hospital, Research, Patient, Heart Rhythm Society, RM, Algorithm, Doctor of Philosophy, IEEE Society on Social Implications of Technology, Medical device, Pharmaceutical industry, Nursing, Medtronic, MD

CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced the findings of a study presented during a late-breaking clinical trial session at the Heart Rhythm Society's (HRS) annual meeting.

Key Points: 
  • Results show significant disparities in mortality rates depending on the method of remote monitoring used.
  • CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ -- Implicity , a leader in remote patient monitoring and cardiac data management solutions, announced the findings of a study presented during a late-breaking clinical trial session at the Heart Rhythm Society's (HRS) annual meeting.
  • The research was conducted in collaboration with the French government's Health Data Hub, using a nationwide database of health information from more than 68,000 patients.
  • What data from this study shows is that clinical improvements vary a lot depending on how remote monitoring is performed.

Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies

Retrieved on: 
Saturday, May 20, 2023
Tricuspid valve, Heart Rhythm Society, EU, Freedom, Chosen-ciphertext attack, Heart failure, Pulmonary vein stenosis, Boston Scientific, BSX, Atrial fibrillation, Learning curve, FLX, ICD, NCDR, Catheter ablation, Arrhythmia, DOAC, Atrial tachycardia, Kaplan–Meier estimator, Heart Rhythm, Patient, Molina Healthcare, Physician, Electrophysiology, Data, Risk, LAAC, Diagnosis, Growth, AF, IDE, Ventricular fibrillation, Recurrence, Cardiology, NYSE, Disease, Safety, Journal of the American College of Cardiology, ATLAS, Medical imaging, Pharmaceutical industry, Nursing, Birth control, Medical device

MARLBOROUGH, Mass., May 20, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. All data were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society, held in New Orleans from May 19-21.

Key Points: 
  • All data were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society, held in New Orleans from May 19-21.
  • The registry data included favorable single procedure success rates, along with efficient procedure times in a broad patient population.
  • Data demonstrated a predictable workflow with a median of 58 minutes within an interquartile range of 40 to 87 minutes.
  • "The data shared at this year's Heart Rhythm meeting showcases the breadth and depth of our cardiology therapies, which spans from diagnosis to treatment of cardiac disease, and highlights the continued growth of our portfolio," said Kenneth Stein, M.D., senior vice president and global chief medical officer, Boston Scientific.

Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

Retrieved on: 
Saturday, May 20, 2023
Heart, Communication, Posture, HRS, Physician, The New England Journal of Medicine, Skin, Medicine, Facial muscles, Investigational device exemption, Heart Rhythm Society, Engineering, IDE, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Medical device

The data further suggests that AVEIR DR could offer new benefits for people with slower-than-normal heart rhythms.

Key Points: 
  • The data further suggests that AVEIR DR could offer new benefits for people with slower-than-normal heart rhythms.
  • The data has been provided to the U.S. Food and Drug Administration (FDA) as part of Abbott's submission for approval of the AVEIR DR device.
  • People who experience a slower-than-normal heart rate have traditionally received a pacemaker, which is a small battery-powered device implanted underneath the skin in the chest.
  • Unlike traditional pacemakers, leadless pacemakers are implanted directly into the heart through a minimally invasive, catheter-based procedure.